REG - OptiBiotix Health - Response to Probiotix Health requisition notice

OptiBiotix HealthAnnouncement

26/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ7028Fa&default-theme=true

RNS Number : 7028F  OptiBiotix Health PLC  26 September 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

ProBiotix Health plc - response to requisition notice

 

OptiBiotix Health plc ("OptiBiotix") notes the announcement made by ProBiotix
Health plc (AQSE: PBX), the life sciences business developing probiotics to
support cardiometabolic health, on 25 September 2024, that it has received a
notice requisitioning a General Meeting (the "Requisition Notice") which has
been served by Platform Securities Nominees Limited, on behalf of Seneca
Partners.

 

OptiBiotix is aware of the Requisition Notice and of the detailed reasons
given by Seneca Partners for resorting to this course of action.

 

OptiBiotix intends to vote its holding of 53,533,333 ordinary shares in
support of the resolutions proposed by Seneca Partners and will publish its
full reasons for supporting the proposals put forward by Seneca Partners in
due course.

 

In the meantime, OptiBiotix believes that it is important that ProBiotix
Health plc clarify its issued share capital which is stated to be 158,166,666
shares carrying voting rights in its announcement of 4 September 2024 but is
stated to be 121,666,666 shares carrying voting rights on its website at
https://probiotixhealth-ir.com/share-information/shareholder-information
(https://probiotixhealth-ir.com/share-information/shareholder-information) .

 

Neil Davidson, Chairman of OptiBiotix Health plc said: "I am sure that Seneca
Partners have only taken this action as an institutional shareholder after
much careful consideration and for good reason. Shareholder activism led by
institutional shareholders is an important aspect of corporate governance and
should generally be seen as an indication that serious failings have been
identified which need to be addressed in the best interests of all
shareholders."

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman           Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)                                Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)                                 Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPFLFITADIEFIS